Biocon Biologics

Biocon Biologics is the biosimilars-focused subsidiary of Biocon Limited, one of India's leading biopharmaceutical companies. Established as a dedicated vertical within the Biocon Group, it develops, manufactures and commercializes biosimilar versions of complex biologic medicines — including insulin, monoclonal antibodies and other recombinant proteins — with the aim of widening access to affordable biologics in India and across global markets. The company operates as part of Biocon's broader biopharmaceuticals business, which spans small-molecule active pharmaceutical ingredients, branded formulations and research services. Biocon Biologics is positioned at the premium, regulated-market end of that portfolio: it pursues development and regulatory filings in the United States and Europe while also serving emerging markets. Its product strategy centers on high-value biosimilar franchises in diabetes, oncology and immunology, areas where originator biologics are expensive and biosimilar competition can meaningfully lower treatment costs. Ownership sits with Biocon Limited, the listed parent whose shares trade on Indian exchanges. Biocon Biologics has attracted external strategic and financial investment to fund its biosimilar pipeline and global commercialization build-out, reflecting the capital-intensive nature of biologic development and manufacturing. The subsidiary operates manufacturing and R&D capacity tied to Biocon's broader science and technology infrastructure in India. As a brand, Biocon Biologics represents the group's ambition to be a global biosimilars player rather than only an API supplier — combining Indian cost advantages in biologics manufacturing with regulated-market quality standards. Its positioning emphasizes affordability, access and scientific credibility, and it competes in a global biosimilars field alongside established players in Europe, the United States and Asia.

Biocon Biologics emerged from Biocon Limited's strategic decision to build a dedicated biosimilars business rather than treat biologics as an extension of its established small-molecule API and formulations operations. Biocon, founded by Kiran Mazumdar-Shaw, had grown from an enzyme and API manufacturer into one of India's most prominent biopharmaceutical companies, and the biosimilars vertical was created to capture the global opportunity presented by patent expiries on major biologic drugs. The subsidiary was formally established in the mid-2010s as a distinct entity within the Biocon Group, allowing the parent to bring in external investors and to structure the capital-intensive biologics business separately. Biocon Biologics pursued a strategy of developing biosimilars for regulated markets — particularly the United States and Europe — while simultaneously commercializing in India and other emerging markets where affordability is a central policy concern. Its portfolio development focused on large-volume biologic categories: insulin for diabetes, and monoclonal antibodies in oncology and immunology. The company invested in manufacturing capacity and analytical characterization capabilities intended to meet the stringent comparability requirements of regulators such as the U.S. FDA and the European Medicines Agency. Partnerships and licensing arrangements with global pharmaceutical companies formed part of its commercialization model in various markets. Over time, Biocon Biologics attracted external equity investment, reflecting both the scale of capital required for biosimilar development and the strategic value investors placed on the franchise. It became a significant contributor to the Biocon Group's biopharmaceuticals segment and a flagship of India's ambition in the global biosimilars industry. The brand's history is thus closely intertwined with Biocon's broader transformation from an Indian API producer into an internationally oriented biopharmaceutical group.

• 2017

  External strategic investment brought into the biosimilars business to fund pipeline and global commercialization.

• 2014

  Biocon Biologics established as a dedicated biosimilars subsidiary within the Biocon Group.

Affordable, high-quality biosimilars for regulated and emerging markets, backed by Indian manufacturing scale and regulated-market quality standards.

• Diabetes

  Biosimilar insulin glargine

• Oncology

  Biosimilar trastuzumab

• Oncology

  Biosimilar bevacizumab

• 2022.02.28

  Reported2022.02.28

  Biocon Biologics announces acquisition of Viatris biosimilars business[1]Biocon Biologics宣布收购Viatris生物类似药业务freepressjournal.in

  Biocon Biologics announced a definitive agreement to acquire Viatris' biosimilars business and related assets. The transaction was expected to close in the second half of 2022, subject to closing conditions, including certain regulatory approvals.

• 2022.01.03

  Reported2022.01.04

  Biocon announces Biocon Biologics–Covidshield Technologies merger[2]Biocon宣布Biocon Biologics与Covidshield Technologies合并businesstoday.in

  Biocon announced that its material subsidiary Biocon Biologics Ltd would merge with Serum Institute of India's wholly owned subsidiary Covidshield Technologies Pvt Ltd, subject to requisite approvals. Biocon Biologics will issue and allot 15% equity shares to Serum on a fully diluted basis.

• 2021.09.17

  Reported2021.09.17

  Biocon Biologics and Serum Institute Life Sciences announce strategic alliance[3]Biocon Biologics与Serum Institute Life Sciences宣布建立战略联盟aninews.in

  Biocon Biologics and Serum Institute Life Sciences announced a strategic alliance covering vaccine access, manufacturing and distribution, and development of antibodies targeting infectious diseases.

• 2020.08.31

  Reported2020.08.31

  Biocon Biologics launches Semglee in the US[4]Biocon Biologics在美国推出Semgleeeconomictimes.indiatimes.com

  Biocon Biologics launched Semglee, a drug to control high blood sugar, in the US.

• Unconfirmed

  Reported2020.07.21

  Biocon Biologics and Voluntis sign licensing agreement[5]Biocon Biologics与Voluntis签署许可协议economictimes.indiatimes.com

  Biocon Biologics' subsidiary Biocon Sdn. Bhd. and Voluntis signed a licensing agreement concerning Insulia, a digital therapeutic product for Type 2 diabetes patients.

• Unconfirmed

  Biocon Biologics appoints MB Chinappa as CFO[6]Biocon Biologics任命MB Chinappa为首席财务官moneycontrol.com

  Biocon Biologics appointed MB Chinappa as its chief financial officer. The article says the appointment was reported on December 7 but does not specify the year.

• 2019.09.24

  Reported2019.09.24

  Biocon Biologics acquires Pfizer Healthcare India research facility assets[7]Biocon Biologics收购辉瑞印度医疗保健公司的研究设施资产businesstoday.in

  Biocon said its subsidiary Biocon Biologics acquired R&D capital assets for a 60,000-square-foot research facility at Ticel Bio Park in Chennai from Pfizer Healthcare India. The financial terms were not disclosed.

• Unconfirmed

  Biocon Biologics acquires Pfizer Healthcare research facility assets[8]Biocon Biologics收购Pfizer Healthcare研究设施资产moneycontrol.com

  Biocon Biologics acquired the R&D capital assets of a 60,000-square-foot research facility at Ticel Bio Park in Chennai from Pfizer Healthcare. The amount was undisclosed.

Read more

1. 1Biocon Biologics宣布收购Viatris生物类似药业务freepressjournal.in
2. 2Biocon宣布Biocon Biologics与Covidshield Technologies合并businesstoday.in
3. 3Biocon Biologics与Serum Institute Life Sciences宣布建立战略联盟aninews.in
4. 4Biocon Biologics在美国推出Semgleeeconomictimes.indiatimes.com
5. 5Biocon Biologics与Voluntis签署许可协议economictimes.indiatimes.com
6. 6Biocon Biologics任命MB Chinappa为首席财务官moneycontrol.com
7. 7Biocon Biologics收购辉瑞印度医疗保健公司的研究设施资产businesstoday.in
8. 8Biocon Biologics收购Pfizer Healthcare研究设施资产moneycontrol.com
9. 9Biocon appoints Susheel Umesh as CCO, Emerging Marketsbiospectrumindia.com
10. 10Biocon subsidiary buys Chennai-based research facility from Pfizer Healthcarethehindubusinessline.com
11. 11Biocon收购维雅瑞生物仿制药资产prnasia.com